VPC
EW icon

Vestal Point Capital’s Edwards Lifesciences EW Stock Holding History

Vestal Point Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-300,000
Closed -$23.5M – 85
2025
Q2 		$23.5M Buy
+300,000
New +$22.4M 1.24% 32
2024
Q4 		– Sell
-275,000
Closed -$18.1M – 83
2024
Q3 		$18.1M Buy
+275,000
New +$20M 1.38% 24
2024
Q1 		– Sell
-225,000
Closed -$17.2M – 64
2023
Q4 		$17.2M Buy
+225,000
New +$15.7M 1.82% 18

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Vestal Point Capital's EW Position: Q3 2025 in Review

Vestal Point Capital sold out of Edwards Lifesciences (EW) in Q3 2025, closing a stake of 300,000 shares — an estimated $23.5M sold.

Vestal Point Capital first reported a position in EW in Q4 2023 and held it in 3 quarters. The position peaked at $23.5M in Q2 2025. 1,254 funds tracked by Wall St. Rank hold EW as of Q3 2025.

  • Vestal Point Capital reported no remaining Edwards Lifesciences position as of Q3 2025 after selling out during the quarter.
  • Vestal Point Capital sold 300,000 Edwards Lifesciences shares in Q3 2025, an estimated $23.5M.
  • Vestal Point Capital first reported a position in Edwards Lifesciences in Q4 2023 and held it in 3 quarters.
  • Vestal Point Capital's Edwards Lifesciences position peaked at $23.5M in Q2 2025.
  • 1,254 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2025.

Based on Vestal Point Capital's 13F filing for Q3 2025, filed 14 Nov 2025.